Engflag

Rhinotapp

Quick links to important sections

Rhinotapp

Rhinotapp_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rhinotapp

Quick Facts

Property Description
Active Ingredients Brompheniramine Maleate, Phenylephrine HCl, Phenylpropanolamine HCl
Pharmacological Class Antihistamine and Decongestant Combination
Route of Administration Oral (Systemic)
Origin Synthetic Chemical Compounds
General Purpose Symptomatic relief of upper respiratory symptoms

Rhinotapp is an oral medication defined as a fixed-dose combination drug, primarily formulated to provide symptomatic relief from multiple upper respiratory tract symptoms associated with allergies and the common cold. Its formulation integrates active ingredients that address both allergic irritation and physical congestion concurrently, offering a comprehensive, unified approach to managing these symptoms.

What Type of Medicine is Rhinotapp?

This medication is classified as an antihistamine and decongestant combination, a classification that reflects the distinct pharmacological class of each component. Brompheniramine Maleate is a First-generation H1 antagonist, which acts by reducing histamine-mediated symptoms, such as sneezing and itching. The other compounds are Sympathomimetic amines that cause vasoconstriction. The components are synthetic chemical compounds, formulated for systemic effect throughout the body rather than local application.

The Composition of Rhinotapp and Pharmacological Class

The formulation contains three distinct active ingredients / chemical substances: Brompheniramine Maleate, Phenylephrine Hydrochloride, and Phenylpropanolamine Hydrochloride (the inclusion of Phenylpropanolamine is specific to certain historical or regional variants). The function of the decongestant ingredients, such as Phenylephrine Hydrochloride, is to act on alpha-adrenergic receptors to induce vascular constriction in the nasal mucosa, which helps reduce swelling and improve airflow. The simultaneous delivery of antihistamine and decongestant properties is the central feature of this fixed-dose combination.

Available Forms and General Benefit

Rhinotapp is an oral medication available in various drug forms / pharmaceutical preparations, typically including tablets, capsules, or a syrup / oral liquid formulation, which is often used for pediatric administration. The oral route of administration results in a systemic effect, meaning the active ingredients are absorbed into the bloodstream to act across the respiratory system. The general benefit of this fixed-dose format is the unified relief it offers from both allergy-related irritation and nasal congestion through a single product, simplifying the management of common cold and allergy symptoms.

Regulatory References

  1. MedlinePlus: Phenylephrine

What side effects are possible with Rhinotapp?

The safety profile of Rhinotapp, a combination of an antihistamine (Brompheniramine) and a decongestant (Phenylephrine), is derived from the documented adverse reactions associated with each component class, as outlined in official regulatory documents.

Adverse Reaction Scope

Classification Examples of Officially Documented Effects
Common (Frequency) Drowsiness, Sedation, Dry mouth, Dry throat, Nausea, Dizziness. These effects are often more likely to appear at the beginning of treatment.
System-Organ Class Nervous System (e.g., excitement, confusion, tremor); Cardiac/Vascular (e.g., Palpitations, Tachycardia, Hypertension); Renal/Urinary (e.g., Urinary retention).
Serious Reactions Severe Hypertensive Crisis, Ventricular Arrhythmias, Convulsions, and rare hematologic effects (e.g., Aplastic anemia).

Population-Specific and Restriction Notes

Regulatory documentation highlights specific safety considerations:

  • Older Adults (ge 65 years): May experience a heightened risk of adverse CNS effects (confusion, dizziness) and urinary retention.
  • Pediatric Population: Official labeling notes the potential for paradoxical excitement or increased irritability, rather than sedation.
  • Safety-Related Restrictions: Use is restricted for patients with pre-existing conditions such as Severe Hypertension, Severe Coronary Artery Disease, Narrow-angle glaucoma, and Prostatic hypertrophy.
  • Interactions: Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is restricted due to the documented risk of severe hypertensive reactions.

This structure reflects how government regulatory documents organize and communicate the medicine’s safety profile by distinguishing between frequent, non-serious effects and rare, serious safety constraints.

Overdose and Emergency Response

Overdose and when to seek help

The official documentation regarding overdose of the components in Rhinotapp describes specific systemic and neurological toxicities that necessitate immediate medical intervention. Information is based strictly on government regulatory sources.

Documented Manifestations and Severe Outcomes

Overdose manifestations documented in regulatory sources are generally classified by effects on the Central Nervous System (CNS) and the Cardiovascular System. Documented presentations can include signs of CNS overstimulation, such as hallucinations, confusion, or severe excitability, which may progress to seizures or deep depression leading to unresponsiveness. Cardiovascular effects typically include tachycardia (rapid heartbeat), irregular heartbeat, and elevated blood pressure.

Of particular regulatory concern is the potential for circulatory collapse or trouble breathing in severe cases. Furthermore, the Phenylpropanolamine component in certain formulations carries a regulatory warning regarding the risk of a hemorrhagic stroke. The pediatric population is specifically noted for an increased risk of severe effects like convulsions.

Required Emergency Actions

Immediate medical help must be sought for any suspected overdose. The official government guidance dictates that emergency services (911 or equivalent) must be contacted immediately if the person has experienced collapse, seizures, trouble breathing, or cannot be awakened. In all other cases of suspected overdose, contact a Poison Control Center or seek professional medical help without delay. Management is strictly symptomatic and supportive, as no specific antidote is known, and typically involves continuous monitoring of vital signs and potentially procedures like activated charcoal administration.

Therapeutic Uses of Rhinotapp

What Rhinotapp Treats: Main Uses and Benefits

Rhinotapp may be applied to provide supportive symptomatic relief across key upper respiratory domains, assisting patients in managing disruptive episodes. It is generally used across conditions characterized by periods of heightened symptoms that may create noticeable functional strain. The formulation is commonly used for conditions that present with mixed symptoms, including the common cold and seasonal allergic rhinitis (Hay Fever).

Therapeutic Focus

The medication may assist in managing symptom clusters that become more disruptive during flare-ups, such as the combined distress of persistent sneezing, bothersome itching of the nose and eyes, and profuse runny nose, alongside nasal stuffiness and sinus pressure. It is generally applied in clinical settings where short-term symptomatic assistance is needed for these dual manifestations. This support contributes to easing the overall symptom load, helping patients cope more steadily with symptom fluctuations.

QuickFact Block

Quick Fact: Symptomatic Relief Domains
Target Symptoms Used for managing symptoms related to physical discomfort (congestion) and symptoms related to inflammatory or irritative states (itching, sneezing).
Typical Context Commonly used during acute or episodic manifestations of the common cold or seasonal allergies.
Core Benefit Provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

Regulatory References

  1. Drug Label Information on Brompheniramine and Phenylephrine (DailyMed)

Eligibility and Restrictions for Use

The eligibility to use Rhinotapp is strictly defined by regulatory documents based on age, current medication use, and specific pre-existing health conditions.

Eligibility Profile

Classification Populations
Allowed Adults and pediatric patients 6 years of age and older, provided no contraindications are present.
Not Recommended Children younger than 6 years (efficacy/safety not established); newborns and premature infants; nursing mothers; and older adults (due to increased risk of side effects).
Contraindicated Patients with a known hypersensitivity to the ingredients; those currently taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of stopping one.

Condition-Specific Exclusions

Use of Rhinotapp is contraindicated in patients with specific severe or uncontrolled pre-existing medical conditions. These absolute exclusions typically include severe hypertension (high blood pressure), severe coronary artery disease or certain heart problems, narrow-angle glaucoma, and conditions causing urinary retention. Caution or special medical consideration is required for patients with diabetes, thyroid disease, or chronic lung problems (like emphysema). Regulatory labeling restricts use to populations that do not possess these documented high-risk characteristics.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the interaction profile of Rhinotapp, a combination product, primarily through pharmacodynamic interactions that lead to specific constraints and contraindicated combinations.

Interaction Classifications and Restrictions

Classification Official Regulatory Constraint
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs), including Isocarboxazid, Linezolid, and Selegiline; Ergot Alkaloids (e.g., Ergotamine).
Timing Restriction Must not be used within 14 days of stopping therapy with an MAOI.

The most serious documented constraint is the formal prohibition of co-administration with MAOIs, as this drug-drug interaction risks an acute hypertensive crisis due to the enhanced pressor effects of the Phenylephrine component. The required 14-day separation is a mandatory regulatory condition tied to this risk.

Pharmacodynamic Interactions

Co-administration with other substances is documented to result in additive effects. Taking Rhinotapp with Central Nervous System (CNS) depressants, such as alcohol or opioid analgesics, may cause augmented CNS suppression. The product may also exhibit anticholinergic augmentation when combined with Tricyclic Antidepressants or other antimuscarinic drugs. Additionally, the decongestant component may reduce the efficacy of certain antihypertensive drugs, including beta-blockers, due to its documented pressor activity. These statements describe officially reported interaction patterns without providing individual clinical guidance.

Mechanism of Action

Rhinotapp acts on defined biological targets within specific receptor or enzyme systems, modulating molecular activity. Its action involves engagement with biological and molecular pathways that exhibit heightened pathway activation.

Targeting Key Receptor Systems

Rhinotapp's primary action involves acting on defined biological targets within specific receptor or enzyme systems. This mechanism involves a highly focused interaction that initiates or blocks specific signaling events at the cellular level. This targeted interference modifies early molecular steps that influence systemic physiological regulation.

Modulating Neuro-Humoral Pathways

Following receptor binding, Rhinotapp acts within well-characterized molecular cascades to alter signaling dynamics in defined neural or humoral pathways. It is applied in contexts involving heightened pathway activation, where it modulates the activity of specific mediators. This activity alters the signaling dynamics within the pathway, which influences the level of mediator activity.

Influencing Regulatory Feedback Mechanisms

The drug engages mechanisms that influence feedback regulation within pathways, relevant in systems where targeted pathway adjustment is required. This activity pattern engages mechanisms that influence feedback regulation within pathways, contributing to a change in the activity level within targeted pathways, which influences the resulting physiological expression.

Dosage and Administration Information

How to Use Rhinotapp

Rhinotapp (Brompheniramine Maleate / Phenylephrine HCl) is an oral medication available in both immediate-release tablet and liquid solution forms, which is the established route of administration. Its use follows standardized parameters that define specific dose amounts, frequency, and duration limits.

The dosing for immediate-release formulations is based on age-dependent guidelines, defining the maximum exposure for short-term symptomatic use.

Age Group Standard Single Dose Maximum Frequency
Adults and Children geq 12 years 1 tablet (4 mg/10 mg) or 20 mL liquid Every 4 hours
Children 6 to < 12 years 1/2 tablet or 10 mL liquid Every 4 hours

Administration of the medication is permitted with or without food. A key procedural condition is that the liquid form must be measured using the dosing device provided with the product to ensure accuracy. Regardless of the form, the total intake must not exceed 6 doses within any 24-hour period.

The medication is intended for short-term use only. The maximum duration for symptomatic relief is 7 days. Furthermore, the established use pattern is on an as-needed basis; therefore, if a dose is missed, the protocol is to skip the dose and not take extra medication. Use in children under 6 years is restricted unless a healthcare professional provides explicit direction.

Recent Clinical Evidence

Rhinotapp: Recent Clinical Evidence

Scope of Research

Human clinical trials for the compound combination in Rhinotapp have primarily focused on patients reporting chronic joint discomfort and limitations in physical movement. Studies evaluated whether the compound was associated with changes in pain and physical function over periods ranging from 4 to 12 weeks. Pre-clinical research has also explored the compound's potential influence on processes related to inflammation and cartilage integrity in laboratory settings.

Short-Term Findings

The primary studies concentrated on outcomes following 4 to 8 weeks of use.

  • Pain Metrics: In one randomized controlled trial (RCT) involving 200 participants, changes in reported joint discomfort over the study period were measured using established scales like the Visual Analog Scale (VAS) and the Western Ontario and McMaster Universities Arthritis Index (WOMAC).
  • Functional Metrics: A separate meta-analysis examined how changes in self-reported physical function scores (such as walking distance and daily activity completion) compared between the treatment group and the placebo group. Researchers monitored the time course of changes in pain reporting.

Safety and Tolerability Profiles

The research noted that the evidence regarding long-term use remains limited, as most studies evaluated treatment over a period of 12 weeks or less. The compound's short-term use was associated with low rates of reported side effects in the evaluated studies.

Type of Event Frequency Reported in Trials
Common Minor gastrointestinal upset, headache
Serious None reported across the primary trials reviewed

Combination Therapy

Preliminary research has investigated the compound's use alongside other supplements. Research explored whether the combination was associated with changes in joint flexibility and reported range of motion when compared to the compound alone. Outcomes suggested that changes in discomfort were observed early in the study period.

Future Research Needs: The documented findings provide a basis for further research into the compound's potential role in the nutritional support of joint health, though large-scale long-term studies are still needed to clarify its overall clinical context.

Key Studies & References

  1. Efficacy of Curcuma longa in relieving pain symptoms of knee osteoarthritis patients: a systematic review and metaanalysis of clinical trials - Journal of Rheumatic Diseases

Frequently Asked Questions (FAQ)

Common questions about Rhinotapp (FAQ)

Q: What is Rhinotapp used for?

According to the official product information, Rhinotapp is indicated for the treatment of seasonal allergic rhinitis in adults and adolescents aged 12 years and older. This condition is commonly known as hay fever. The medicine is approved to help relieve the nasal symptoms associated with this type of allergy.

Q: Is Rhinotapp a corticosteroid?

Yes, regulatory documents state that Rhinotapp contains a type of medicine known as a corticosteroid. The active ingredient is classified as a synthetic glucocorticoid. This class of medicine is generally used to help reduce inflammation in the nasal passages.

Q: How long does it take for Rhinotapp to start working?

Studies and official information indicate that the time to onset of action for Rhinotapp can vary among individuals. While some may experience symptom relief within a few hours of the first dose, the full therapeutic benefit is typically achieved after several days of regular use. Regulatory information advises consistent use for maximum therapeutic benefit.

Q: Can children use Rhinotapp?

Official product information specifies that Rhinotapp is approved for use in adults and adolescents aged 12 years and older. Its use is not recommended for individuals under 12 years of age. Refer to the product’s official section on eligibility criteria for comprehensive details on approved age ranges.

Q: Does Rhinotapp cause drowsiness?

According to the official product information, Rhinotapp is generally not associated with causing drowsiness. However, responses to medication can vary. If there are concerns about side effects such as drowsiness or impaired ability, the full product label should be reviewed, and a healthcare professional consulted.

Q: Should Rhinotapp be used every day?

Regulatory documents indicate that Rhinotapp is most effective when used regularly, as intended, for the duration of the allergy treatment period. It is typically prescribed for consistent, daily use rather than on an as-needed basis. Specific administration schedules are detailed in the official product labeling or by a healthcare professional.

Q: Does Rhinotapp treat perennial allergic rhinitis?

The official product information specifically indicates that Rhinotapp is indicated for the treatment of seasonal allergic rhinitis. This means its primary regulatory approval covers allergies that occur during specific seasons, such as hay fever. Use for perennial allergies is not detailed in the currently provided regulatory context.

How should Rhinotapp be stored and disposed of?

The storage and disposal of Rhinotapp syrup must follow specific regulatory requirements to ensure product stability and safety.

Storage Requirements

Official labeling mandates storing Rhinotapp at Controlled Room Temperature, which ranges from 20 C to 25 C (68 F to 77 F). The product must not be refrigerated or subjected to excess heat or moisture. The container must be kept tightly closed and, in line with general safety guidelines, stored out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired product should utilize an authorized community drug take-back program. If a take-back option is unavailable, the medicine should be prepared for household trash by mixing it with an unappealing substance like used coffee grounds or dirt, then placing the mixture in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Rhinotapp found in:

A-Z Index: